Abstract:Background One key objective of a multi-regional clinical trial (MRCT) is to use the trial results to ‘bridge’ from the global level to local region in support of local registrations. However, data from each individual country are typically limited and the large number of countries will increase the chance of false positive findings. Purpose Graphical tools to facilitate identification of potential outlying countries could be useful for country-level assessment. Existing methods such as funnel plot and expected range of treatment effect can substantially increase the false positive rate. The expected range approach can also have a very low power when there are a large number of small countries, which is typical in a MRCT. Methods In this article, we apply normal probability plots, commonly used as a diagnostic tool in linear regression analysis, to assess the differences among countries. Evidence of possible inconsistency, which incorporates both the estimated treatment effect and sample size, is plotted against its expected order statistic. Results A simulation study is conducted to assess the impact of the negative correlation among residuals due to unequal sample sizes among countries and the performance of the proposed methods compared to existing approaches. The proposed methods tend to have a balanced consideration with substantially smaller false positive rate and reasonable probability to identify outlying countries in realistic scenarios. Limitations While much lower than that of commonly used methods, the false positive rates of the proposed methods are not strictly controlled. This may be acceptable for these graphical tools with intention to flag potential outliers for investigation. Conclusions We recommend routine use of normal probability plots in MRCTs as a tool to identify potential outliers. If the normal probability plot is approximately linear but has heavy tails with a few outlying countries, these potential outliers should be examined carefully to understand the possible reasons.

Practical Recommendations for Regional Consistency Evaluation in Multi-Regional Clinical Trials with Different Endpoints

Qualitative Consistency of Treatment Effects in Multiregional Clinical Trials

Two methods for assessing consistency probability in multiregional clinical trials: a comparison study

Challenges from Variation across Regions in Cost Effectiveness Analysis in Multi-Regional Clinical Trials

Regional efficacy evaluation in multi‐regional clinical trials using a discounting factor weighted Z test

Considerations on Subgroup Analysis in Design and Analysis of Multi-Regional Clinical Trials

Research report on guidance for the multi-regional clinical trials

Graphical assessment of consistency in treatment effect among countries in multi-regional clinical trials

Multi-regional clinical trials and global drug development

Bridging Continual Reassessment Method for Phase I Clinical Trials in Different Ethnic Populations

Analysis of influencing factors on observed regional difference in treatment effects in clinical trial

Application of estimand framework to the design and analysis of multi-regional clinical trials

A Design For Survival Studies: A Multi-regional Trial With Unrecognized Heterogeneity

A Bayesian approach based on discounting factor for consistency assessment in multi-regional clinical trial

Bayes shrinkage estimator for consistency assessment of treatment effects in multi‐regional clinical trials

Inference of treatment effect and its regional modifiers using restricted mean survival time in multi-regional clinical trials

Multivariate Rank-Based Analysis of Multiple Endpoints in Clinical Trials: A Global Test Approach

The necessary conduct: Exploratory multiregional clinical trials in East Asia

RegionSizeR- A Novel App for Regional Sample Size Planning in MRCTs

Some statistical methods for multiple endpoints in clinical trials

Robust EM Continual Reassessment Method in Oncology Dose Finding